Findings

What do systematic reviews say?

28 questions · 28 findings · 11 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 3.6%GRADE not reported 0 · 0%Very low 8 · 28.6%Low 9 · 32.1%Moderate 9 · 32.1%High 1 · 3.6%

Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs Radiotherapy alone

Disease or progression‐free survival Median · women with locally advanced cervical cancer

Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in disease‐ or progression‐free survival Median compared with radiotherapy alone (moderate certainty).

1 finding from 1 review

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
HR 0.75 [0.53, 1.05]
3 studies · 571 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs PLD alone

Progression‐free survival · recurrent platinum‐resistant EOC

Summary of findings 3: PLD with chemotherapy showed no clear difference in progression‐free survival (PFS) compared with PLD alone (low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.94 [0.73, 1.22]
2 studies · 353 participants
Low

Summary of findings 2: PLD alone vs other conventional chemotherapy

Progression‐free survival · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes progression‐free survival (PFS) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.94 [0.85, 1.04]
4 studies · 1803 participants
Very low

EGFR tyrosine kinase inhibitor (TKI) vs observation

Progression‐free survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 1.05 [0.9, 1.23]
1 study · 835 participants
Very low

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 4): targeted therapy agent… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
HR 0.64 [0.45, 0.92]
5 studies · 883 participants
Moderate

Hysterectomy (simple or radical) with radiotherapy vs Radiotherapy alone

Progression‐free survival (PSF) · women with locally advanced cervical cancer

Hysterectomy (simple or radical) with radiotherapy showed no clear difference in progression‐free survival Median compared with radiotherapy alone (low certainty).

1 finding from 1 review

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
HR 0.77 [0.54, 1.1]
1 study · 256 participants
Low

Intervention not reported

Progression‐free survival1 · Patients with advanced non‐small cell lung cancer

The intervention showed no clear difference in progression‐free survival1 (low certainty).

1 finding from 1 review

Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
HR 0.91 [0.83, 1]
4 studies · 2018 participants
Low

IRI with fluoropyrimidines vs single agent IRI

Progression‐free survival (PSF) · patients with advanced and/or metastatic colorectal cancer

IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).

1 finding from 1 review

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
HR 0.68 [0.53, 0.83]
3 studies · 600 participants
Moderate